Parkinson's Disease - Epidemiology Forecast to 2029

Parkinson's disease (PD) is a progressive disorder of the nervous system that affects movement by causing shaking, stiffness, and difficulty with walking, balance, and coordination (National Institute on Aging, 2017; Mayo Clinic, 2020). PD is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression (World Health Organization, 2020). PD is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, affecting 1-2% of individuals ages 65 years and older worldwide (Mhyre et al., 2012; Kowal et al., 2013).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for PD in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex, age, and HY clinical staging.

The following data describes epidemiology of PD. In the 7MM, the publisher's epidemiologists forecast an increase in the diagnosed prevalent cases of PD from 2,434,438 cases in 2019 to 2,999,337 cases in 2029, at an AGR of 2.32% over the forecast period. Men accounted for slightly more diagnosed prevalent cases of PD than women in the 7MM, and is one of the most common chronic progressive neurodegenerative disorders in the elderly population, as PD predominantly affects older adults. These trends are reflected in the publisher’s forecast for the diagnosed prevalent cases for the 7MM.

Scope

• The Parkinson’s Disease (PD) Epidemiology Report provides an overview of the risk factors and global trends of PD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by sex and age (ages ≥18 years). The diagnosed prevalent cases of PD are further segmented by Hoehn and Yahr (HY) clinical staging (stages I, II, III, IV, and V), and grouped into early (equivalent to HY clinical stages I-II), moderate-advanced (equivalent to HY clinical stages III-V), and advanced (equivalent to HY clinical stages IV-V).
• The PD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Parkinson’s Disease Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global PD market.
• Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD therapeutics in each of the markets covered.
• Understand magnitude of PD population by clinical staging.